A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: HER2 Positive Breast Cancers
Interventions: DRUG: Tucatinib (ONT-380)|DRUG: T-DM1
Sponsor: Seagen Inc.